Telix to present further Phase III ZIRCON data in ‘Game Changing Session’ at EAU 2023
Telix is pleased to be presenting further data from the Phase III ZIRCON study in a ‘Game Changing Session’ at The Annual Congress of the European Association of Urologists in Milan, Italy on Saturday 11 March.
As the leading specialised event for urologists in Europe, EAU23 (March 10-13) presents an opportunity for urologists at all stages in their career to enhance their medical training and discover the latest in urological research.
As a part of the program, Prof. Dr. Peter Mulders from Radboud University Nijmegen Medical Centre will present further data from the Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC).
Watch our series of short video explainers below on the Phase III ZIRCON study and the potential of TLX250-CDx
In addition to this ‘Game Changing Session’, Telix’s carbonic anhydrase IX (CAIX) targeting investigational assets will feature in two other presentations at the conference.
The Telix team looks forward to seeing you at EAU23 and sharing more about the company’s PSMA-PET imaging candidate and our broad theranostic research pipeline across prostate, renal and bladder cancers.
For more information including how to register, visit: https://eaucongress.uroweb.org/
EAU23 presentation details are as follows:
Title: 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study
Session: Game Changing Session, Yellow Area, eURO Auditorium 2
Presenting Author: Peter Mulders, Radboud UMC
Date: Saturday, 11 March 2023
Time: 10:00 AM to 10:15 AM
Title: 89 Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP) – A phase I trial of a novel staging modality for urothelial carcinoma
Session: Clinical Trials in Progress Session, Blue Area, Room 1
Presenting Author: Dickon Hayne, University of Western Australia
Date: Sunday, 12 March 2023
Time: 10:45 AM to 12:15 PM
Abstract ID: A0520
Title: Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition
Session: Abstract Session 55, Blue Area, Room 1
Presenting Author: Egbert Oosterwijk, Radboud UMC
Date: Monday, 13 March 2023
Time: 10:45am to 12:15pm
Abstract ID: A1032